CJC-1295 no DAC + Ipamorelin

Description

CJC-1295 Ipamorelin Blend (No DAC) (CJC-1295 CAS: 446036-97-1) (Ipamorelin CAS: 170851-70-4) is a laboratory-formulated research peptide blend combining two mechanistically distinct synthetic growth hormone secretagogues, supplied by AusPepLabs for laboratory and analytical research applications. This CJC-1295 Ipamorelin Blend pairs CJC-1295 No DAC (Modified GRF 1-29), a GHRH receptor agonist activating cAMP/PKA signaling, with Ipamorelin, a selective GHS-R1a agonist activating Gq/PLC-dependent calcium signaling. Each vial is independently verified to ≥99% HPLC purity with a Certificate of Analysis available on request. For scientific research use only.

Why Research Laboratories Select This CJC-1295 Ipamorelin Blend

The CJC-1295 Ipamorelin Blend No DAC is one of the most studied dual-secretagogue combinations in current growth hormone axis research. By combining a GHRH receptor agonist with a selective ghrelin receptor agonist, this blend enables laboratories to investigate dual-pathway GH secretagogue signaling, receptor cross-talk, and complementary second messenger pathway interactions in a single experimental system.

• Dual receptor targeting – GHRHR via CJC-1295 No DAC and GHS-R1a via Ipamorelin simultaneously
• Complementary signaling pathways – cAMP/PKA and Gq/PLC calcium pathways studied together
• Each component in the CJC-1295 Ipamorelin Blend independently verified to ≥99% HPLC purity
• No-DAC formulation – shorter-acting pulsatile dynamics versus sustained DAC-based studies
• Ipamorelin component studied for selectivity – minimal cross-reactivity with other pituitary pathways
• Lyophilized format ensures stability and reproducibility across experimental runs